Skip to Content

Join the 'Rivastigmine' group to help and get support from people like you.

Rivastigmine News

Dementia Drug May Lower Risk of Falls Among Parkinson's Patients

Posted 13 Jan 2016 by Drugs.com

TUESDAY, Jan. 12, 2016 – A widely used dementia drug shows potential in reducing the risk of falls among Parkinson's patients, new research suggests. "With the degeneration of dopamine-producing nerve cells, people with Parkinson's often have issues with unsteadiness when walking. As part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate – making it extremely difficult to pay attention to walking," said study lead author Emily Henderson, from the University of Bristol in England. The study included 130 people with Parkinson's disease who had fallen in the past year. Half took the drug rivastigmine (Exelon), while the other half took a placebo. After eight months, those who took the rivastigmine capsules were much steadier when walking and 45 percent less likely to fall than those who took the placebo, according to the researchers. ... Read more

Related support groups: Parkinson's Disease, Dementia, Alzheimer's Disease, Exelon, Mild Cognitive Impairment, Rivastigmine, Arteriosclerotic Dementia, Parkinsonian Tremor, Parkinsonism, Prevention of Falls, Lewy Body Dementia, Arteriosclerotic Dementia w/ Depressive Features

Dementia Meds May Lead to Harmful Weight Loss: Study

Posted 3 Aug 2015 by Drugs.com

MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead author Dr. Meera Sheffrin, a geriatrics fellow in the School of Medicine, at the University of California, San Francisco, said in a university news release. One expert said the findings point out a common problem for Alzheimer's patients. "Weight loss is a concern, not only for patients but also for their overwhelmed caregivers, who keep struggling with multiple challenges, including providing their ... Read more

Related support groups: Weight Loss, Dementia, Alzheimer's Disease, Aricept, Donepezil, Exelon, Mild Cognitive Impairment, Rivastigmine, Arteriosclerotic Dementia, Galantamine, Reminyl, Cachexia, Razadyne, Cognex, Namzaric, Razadyne ER, Tacrine, Arteriosclerotic Dementia w/ Depressive Features, Aricept ODT, Lewy Body Dementia

Novartis Exelon Patch Now FDA Approved to Treat Patients Across all Stages of Alzheimer's Disease

Posted 30 Jun 2013 by Drugs.com

EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ – The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease (AD) with Exelon Patch 13.3mg/24h.  Exelon Patch is now the first and only transdermal therapy approved to treat patients with mild, moderate and severe AD. "Millions of patients currently suffer from Alzheimer's, a debilitating and heartbreaking disease marked by a decline in overall cognition and function," said John Schall, CEO, Caregiver Action Network.  "While there is currently no cure, there is help for patients along the journey, and new treatment options play an important role." The approval of Exelon Patch for severe AD was based on the pivotal ACTION (ACTivities of Daily Living and CognitION in Patients with Severe Dementia of the A ... Read more

Related support groups: Dementia, Alzheimer's Disease, Exelon, Rivastigmine

Alzheimer's Drugs May Benefit Heart, Study Finds

Posted 5 Jun 2013 by Drugs.com

WEDNESDAY, June 5 – Drugs used to treat early-stage Alzheimer's disease may also reduce patients' risk of heart attack and death, according to a new study. Researchers followed more than 7,000 Alzheimer's disease patients in Sweden for more than three years. Those taking cholinesterase inhibitors had a 38 percent lower risk of heart attack, a 26 percent lower risk of death from cardiovascular causes such as stroke and a 36 percent lower risk of death from any cause, compared to those who did not take the drugs. Patients who took the highest recommended doses of cholinesterase inhibitors (ChEIs) had the lowest risk of heart attack or death – 65 percent and 46 percent lower, respectively, than those who never took the drugs, according to the study, which was published online June 5 in the European Heart Journal. "If you translate these reductions in risk into absolute figures, it means ... Read more

Related support groups: Heart Attack, Alzheimer's Disease, Aricept, Myocardial Infarction, Donepezil, Exelon, Cardiovascular Risk Reduction, Rivastigmine, Galantamine, Reminyl, Razadyne, Razadyne ER, Aricept ODT

Higher Dose of Novartis Drug Exelon Patch Approved By FDA for Patients With Mild to Moderate Alzheimer's Disease

Posted 4 Sep 2012 by Drugs.com

EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ – The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease. The new 13.3 mg/24 h dosage strength of Exelon Patch provides physicians with a new treatment option for patients who are experiencing a decline in overall function and cognition. "Alzheimer's disease is marked by progressive symptomatic decline, resulting in an increasingly large physical and emotional challenge for the patient and caregiver," said Jeffrey Cummings, MD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. "Having multiple options for the treatment of mild to moderate Alzheimer's disease will help physicians better care for patients with the hope of improving function and cognition." Approval of Exelon Patch 13.3 mg/24 h was ... Read more

Related support groups: Parkinson's Disease, Dementia, Alzheimer's Disease, Exelon, Rivastigmine

Some People With Alzheimer's Take Conflicting Drugs

Posted 28 Oct 2011 by Drugs.com

FRIDAY, Oct. 28 – Many Alzheimer's patients who take cholinesterase inhibitors to slow their brain disease also take drugs that counter the effects of those Alzheimer's medications, a new study says. Clinical trials have shown that cholinesterase inhibitors such as Aricept (donepezil) have a modest impact on the functional and cognitive decline caused by Alzheimer's disease, noted the researchers at the Group Health Research Institute in Seattle. "Cholinesterase inhibitors are today's primary therapy for slowing Alzheimer's disease," study leader Denise Boudreau said in an institute news release. "Anticholinergic properties are often found in drugs commonly used to treat gastrointestinal disorders, allergies, urinary incontinence, depression and Parkinson's disease, and they can have negative effects on cognition and function in the elderly. There's concern that if someone is taking ... Read more

Related support groups: Benadryl, Diphenhydramine, Oxybutynin, Alzheimer's Disease, Meclizine, Aricept, Dramamine, Donepezil, Ditropan, Exelon, Oxytrol, Cogentin, Benztropine, Scopolamine, Benadryl Allergy, Antivert, Artane, Bonine, Gelnique, Transderm-Scop

Anti-Delirium Drug May Harm Critically Ill Patients

Posted 4 Nov 2010 by Drugs.com

THURSDAY, Nov. 4 – The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates. When given to critically ill patients, it may even be linked to a more severe type of delirium, a longer intensive care stay and increased mortality, the new study suggests. The findings could influence treatment protocols for the most severely ill Alzheimer's and Parkinson's disease patients for whom Exelon is a standard treatment. In a news release, the Dutch team, led by Dr. Maarten M J van Eijk and Dr. Arjen J.C. Slooter of the University Medical Centre in Utrecht, concludes that "since (the) findings of our study show that rivastigmine does not decrease duration of delirium and might increase mortality in critically ill patients, we do not recommend treatment of delirium with rivastigmine for patients in ... Read more

Related support groups: Exelon, Rivastigmine

Ask a Question

Further Information

Related Condition Support Groups

Parkinson's Disease, Alzheimer's Disease, Lewy Body Dementia

Related Drug Support Groups

Exelon

Rivastigmine Patient Information at Drugs.com